|
Clinicopathological and molecular parameters
|
Overall (%)
|
p14 ARF promoter methylation profile
|
|---|
|
Unmethylated
|
Dense or partial methylation
|
P value
|
|---|
|
Age, years, mean ± SD
| |
64 ± 12
|
69 ± 10
|
0.20571
|
|
Gender
| |
|
Male
|
16 (46%)
|
5 (45.5%)
|
11 (45.8%)
|
0.9833
|
|
Female
|
19 (54%)
|
6 (54.5%)
|
13 (54.2%)
|
|
Type of tissue
| | | | |
|
Tumor
|
35
|
11 (31%)
|
24 (69%)
|
0.0019
|
|
Adjacent colon mucosa
|
35
|
24 (69%)
|
11 (31%)
|
|
Tumor location
|
|
Right side
|
10 (29%)
|
3 (27.3%)
|
7 (29.2%)
|
>0.05
|
|
Left side
|
25 (71%)
|
8 (72.7%)
|
17 (70.8%)
| |
|
Differentiation
| |
|
Well or moderate
|
22 (62.9%)
|
10 (90.9%)
|
12 (50%)
|
0.0270
|
|
Poor or mucinous
|
13 (37.1%)
|
1 (9.1%)
|
12 (50%)
| |
|
Clinical stage
| |
|
Stage I
|
3 (8.6%)
|
-
|
3 (12.5%)
|
0.46742
|
|
Stage II
|
17 (48.6%)
|
5 (45.4%)
|
12 (50%)
| |
|
Stage III
|
9 (25.7%)
|
3 (27.3%)
|
6 (25%)
| |
|
Stage IV
|
6 (17.1%)
|
3 (27.3%)
|
3 (12.5%)
| |
|
p53 immunohistochemistry
| |
|
Negative pattern
|
5 (14.3%)
|
3 (27.3%)
|
2 (8.3%)
|
0.02752
|
|
Diffuse pattern
|
13 (37.1%)
|
6 (54.5%)
|
7 (29.2%)
| |
|
Restricted overexpression
|
17 (48.6%)
|
2 (18.2%)
|
15 (62.5%)
| |
|
MDM2 immunohistochemistry
| |
|
Negative
|
12 (34.3%)
|
7 (63.6%)
|
5 (20.8%)
|
0.0223
|
|
Overexpression
|
23 (65.7%)
|
4 (36.4%)
|
19 (79.2%)
| |
|
p21 immunohistochemistry
| |
|
Loss to mild
|
9 (25.7%)
|
6 (54.5)
|
3 (12.5%)
|
0.01462
|
|
Moderate to high
|
26 (74.3%)
|
5 (45.5)
|
21 (87.5%)
| |
|
TP53 mutational status
| |
|
Mutation present
|
10 (28.6%)
|
5 (45.5%)
|
5 (20.8%)
|
0.2266
|
|
No mutation detected
|
25 (71.4%)
|
6 (54.5%)
|
19 (79.2%)
| |
|
MSI status
| |
|
MSI-H
|
11 (31.4%)
|
1 (9.1%)
|
10 (41.7%)
|
0.0539
|
|
MSS
|
24 (68.6%)
|
10 (90.9%)
|
14 (58.3%)
| |
- Abbreviations: MSI, Microsatellite instability, MSI-H, microsatellite instability-high; MSS, microsatellite-stable.
- 2Two-sided two-sample t-test.
- 2Two-tailed Fisher’s exact test.
